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Coronavirus disease 2019 (COVID- 19), a multi- organ disease caused by severe acute 
respiratory syndrome coronavirus 2 (SARS- CoV- 2), continues to challenge health and 
care systems around the globe. The pandemic has disrupted acute neurology services 
and routine patient care and has impacted the clinical course in patients with chronic 
neurological disease. COVID- 19 appears to have exposed inequalities of societies and 
healthcare systems and had a disproportionate impact on already vulnerable commu-
nities. The next challenge will be to set up initiatives to stop disparities in all aspects 
related to COVID- 19. From the medical perspective, there is a need to consider inequali-
ties in prevention, treatment and long- term consequences. Some of the issues of direct 
relevance to neurologists are summarised. With this appraisal, the European Academy 
of Neurology NeuroCOVID- 19 Task Force intends to raise awareness of the potential 
impact of COVID- 19 on inequalities in healthcare and calls for action to prevent disparity 
at individual, national and supranational levels.
K E Y W O R D S
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CoV- 2
INTRODUC TION
Coronavirus disease 2019 (COVID- 19), a multi- organ disease caused 
by severe acute respiratory syndrome coronavirus 2 (SARS- CoV- 2), 
continues to challenge health and care systems around the globe. In 
only 12 months since the report of the index case in Wuhan, China, 
the pandemic has resulted in more than 83.2 million confirmed cases 
and 1.8 million deaths worldwide.[1] From a neurological perspec-
tive, the pandemic has not only disrupted acute services but also 
routine patient care, through limited provision of resources and hos-
pital avoidance behaviour.[2] Even in the absence of SARS- CoV- 2 
infection, people with chronic neurological conditions including 
dementia, Parkinson´s disease and epilepsy currently have a higher 
risk of clinical progression and complications.[3– 8] The disruptions 
to patient care and consequent mental distress are considered po-
tential trigger factors for this observation.[9,10]
INEQUALITIES E XPOSED BY COVID - 19: 
GENER AL A SPEC TS
COVID- 19 appears to have exposed inequalities of societies and 
healthcare systems and had a disproportionate impact on already vul-
nerable communities. There is an increasing body of evidence that the 
pandemic continues to have the heaviest impact on the lives of people 
living in difficult socioeconomic circumstances. The incidence and mor-
tality of COVID- 19 are also disproportionately higher in certain ethnic 
minority groups, both in the United States and Europe. In London, 
Asian people had higher odds of death from COVID- 19 compared to 
White people.[11] In another study from the United Kingdom, Black 
and Asian individuals had a greater than four- and two- fold increased 
risk of COVID- 19 infection, respectively, compared to White study 
members.[12] In a study from Barcelona, the incidence of COVID- 19 
showed an inverse association with mean income.[13] Data from the 
Stockholm region revealed higher COVID- 19 mortality in young and 
socially vulnerable populations.[14] Migrants and refugees are among 
the vulnerable groups, many of whom have to live, travel and work 
in conditions where physical distancing and recommended hygiene 
measures are essentially impossible because of poor housing condi-
tions and economic precarity.[15] The World Health Organization 
(WHO) anticipates that people who have both COVID- 19 and other 
infectious diseases such as tuberculosis (TB) may have poorer treat-
ment outcomes.[16] This hypothesis is generated from the assump-
tion that a lower detection rate for TB during the pandemic can be 
expected, which may translate into a higher rate of TB- related deaths. 
Non- communicable diseases are also highly prevalent in refugee popu-
lations, such as type 2 diabetes mellitus, and are known to increase the 
risk for severe COVID- 19.[17]
    |  3DISPARITIES IN COVID- 19: A CALL FOR PREVENTIVE MEASURES
Moreover, there are consistently higher intensive care unit 
(ICU) admission and fatality rates in male COVID- 19 patients.[18] 
Genetics, immunological responses and hormonal mechanisms may 
play a role, and sociocultural factors such as smoking and handwash-
ing rates have also been postulated.[19,20]
NEUROLOGIC AL MANIFESTATIONS OF 
COVID - 19
There is increasing evidence that SARS- CoV- 2 infection can also af-
fect the nervous system.[21,22] In a prospective study of 239 peo-
ple with COVID- 19 from Turkey, 34.7% had neurological symptoms.
[23] Headache, myalgia, anosmia, ageusia, impaired consciousness and 
psychomotor agitation were the most frequent neurological findings in 
COVID- 19 patients according to an international survey conducted by 
the European Academy of Neurology (EAN).[24] COVID- 19- associated 
encephalopathy and cerebrovascular disorders are further neurologi-
cal manifestations, and are associated with unfavourable short- term 
outcomes compared to age- and sex- matched historical non- COVID- 19 
cohorts.[25– 27] Additional complications include para- and postin-
fectious disorders (e.g. Guillain- Barré syndrome, acute disseminated 
encephalitis) and neuroinvasive disease.[28,29] The latter is character-
ized by neuronal injury in the presence of SARS- CoV- 2 replication in 
the central nervous system (CNS) and a local inflammatory response.
[30] Of note, a case of COVID- 19 meningitis without pulmonary in-
volvement has been reported.[31] Several studies demonstrated an 
increased risk of secondary neurological complications in hospitalized 
patients with COVID- 19.[32,33] Moreover, biomarkers for CNS injury 
in cerebrospinal fluid (CSF) are elevated in COVID- 19 and associated 
with neurological symptoms and disease severity.[34]
The underlying biology of COVID- 19 with extensive inflamma-
tion predicts that longer- term neurological manifestations are to be 
expected, especially in older individuals and people susceptible to 
autoimmune disease. Longer- term consequences of NeuroCOVID- 19 
are being researched; further insights are expected from interna-
tional registries such as ENERGY, a database set up by the EAN.[35]
INEQUALITIES RE VE ALED BY COVID - 19: 
RELE VANCE FOR NEUROLOGY
The Global Burden of Disease 2017 study disclosed that neuro-
logical disorders are the third most common cause of disability and 
premature death in the European Union.[36] Advanced age and co-
morbidities are significant risk factors for COVID- 19- related fatal-
ity.[37,38] Many diseases of older age are neurological disorders, 
and elderly patients have a higher likelihood of pre- existing medi-
cal conditions. People with neurological disorders have more severe 
COVID- 19 and higher mortality.[39,40] Thus, the sheer number of 
patients at risk for unfavourable outcomes from COVID- 19 based 
on age and comorbidities underpins the importance of neurology 
in the multidisciplinary care of these patients.[41] Maintenance of 
acute neurology services, inpatient and outpatient care, and neu-
rorehabilitation are needed more than ever. However, during this un-
precedented public health crisis, these services are vulnerable and 
disruption may have a disproportionate impact on certain groups.
[42] In Greece, hospitalization for acute stroke and acute coronary 
syndrome declined during the first wave of the pandemic, indicat-
ing medical care avoidance behaviour.[31] In Slovakia, the analysis 
of the nationwide stroke registry revealed a fall in the number of 
stroke patients, which did not translate in a drop in the quality of 
acute stroke care compared to pre- COVID- 19 times.[43] In contrast, 
the overall incidence of stroke remained unchanged in the French 
Alsace region, but fewer patients presented within the therapeutic 
time window.[44] In Northwest Spain, a decrease in the number of 
patients benefiting from reperfusion therapies was found, with a 
delay in out- of- hospital and door- to- needle times.[45] A similar find-
ing was reported from Hungary.[46]
Reports that outpatient clinics, neurology wards and rehabili-
tation facilities were either closed, reduced in capacity, or shifted 
toward people recovering from respiratory infection are worrying.
[47] Remote consultation can bridge gaps in outpatient care in some 
neurological subspecialties.[48] Diagnosing neurological diseases 
is often dependent on physical neurological examination. As video 
conferencing and smartphone technologies have improved tremen-
dously, even parts of the neurological examination can be applied 
via video consultation.[49,50] It needs to be considered, however, 
that technical equipment may not always be available at hub sites, 
virtual consultation unavailable due to lack of reimbursement, or in- 
house priorities shifted towards acute care of COVID- 19 patients. 
Moreover, the necessity of familiarity with the technology means 
that problems may arise for some groups, for example, older peo-
ple.[51] These problems might be exacerbated if family members 
are unable to assist because of the necessity of social distancing. 
Availability of digital infrastructure and literacy is also related to so-
cioeconomic status, so this represents another area where measures 
need to be considered to avoid discrimination.[52]
Isolation can result in psychological distress among patients, fam-
ilies and healthcare staff. In a study from London, patients reported 
emotional, cognitive and physical concerns, and greater vulnerability 
to isolation and economic hardship.[10] Families and carers reported 
increased distress arising from hospital lockdown. Healthcare work-
ers reported distress, anxiety and reduced social support. Elderly 
people may also face discrimination. In a study from Israel, societal 
views of older adults were studied; perceptions of vulnerability and 
burden to society during the COVID- 19 outbreak were reported.[53] 
There might be a shortage of mobile nurses for people who require 
care at home. Moreover, discharge to long- term care homes after a 
hospital stay for COVID- 19 or other reasons may be delayed not only 
by limited nursing capacity but also by the fear of infecting nursing 
home residents and healthcare staff despite negative testing.
The pandemic has also disrupted residency programmes due 
to a relocation of manpower and reduction of capacity for outpa-
tient service and at wards. A survey from the Resident and Fellow 
Section of the EAN revealed that 79% of the respondents felt that 
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the pandemic will likely have a serious impact on their training and 
career.[54]
Evidence- based guidelines from scientific societies or govern-
ment bodies should support identification of medical standards 
avoiding such inequities. However, evidence is sparse in a situation 
facing a new disease within a pandemic. Few recommendations 
were developed with urgency to address this shortfall including the 
EAN recommendations for management of patients with neurologi-
cal diseases during the COVID- 19 pandemic.[55] Many of the above 
issues are addressed in these recommendations.
ACCESS TO COVID - 19 DIAGNOSTIC S, 
VACCINATION AND THER APY: STOPPING 
INEQUALIT Y BEFORE IT HAPPENS
The pandemic caused an acute shortage of essential supplies. The 
WHO has established a COVID- 19 supply chain system to fill gaps, 
ensure quality and help countries navigate supply issues.[56] In ad-
dition to efforts directed at promoting information campaigns about 
COVID- 19, the WHO provided technical support, virtual training, 
equipment and supplies to boost testing capacity around the world.
In low- and middle- income countries, the direct and longer- term 
socioeconomic consequences of the pandemic may be even more 
extensive due to fragility of pre- existing healthcare systems and 
shortage of resources.[57] The next challenge will be to set up initia-
tives to stop inequality in all aspects related to COVID- 19. From the 
medical perspective, there is a need to consider disparities in pre-
vention, treatment and long- term consequences. Here, we provide 
a brief summary of considerations. We acknowledge that this list is 
incomplete, needs to be adapted to circumstances, and may not be 
applicable in every setting.
1. The public health strategy of flattening incidence curves by 
primary prevention is a multifaceted process. Timely diagnosis 
of individuals with COVID- 19 requires unrestricted and wide-
spread access to appropriate diagnostic testing. To prevent 
inequitable access to testing, neighbourhoods in lower- income 
areas and communities with high proportions of ethnic minority 
residents and refugees may need to be actively prioritized 
for mass testing. Limited health literacy has the potential to 
undermine efforts to reduce viral transmission, as reported in 
a study from Australia.[58] People with low health literacy had 
poorer understanding of COVID- 19 symptoms, were less able 
to identify behaviours to prevent infection, and experienced 
more difficulty finding information and understanding govern-
ment messaging about COVID- 19. Outreach schemes should be 
combined with educational initiatives regarding the importance 
of COVID- 19 testing.
2. Isolation of individuals diagnosed with COVID- 19 and iden-
tification and quarantine of close contacts is another key step. 
For people living in challenging socioeconomic circumstances, 
sick leave, quarantine and COVID- 19 in family members has far 
greater consequences. This disproportionate impact can be ex-
panded to issues such as home schooling. Moreover, people with 
lower income are more likely to experience overcrowding in their 
household,[59] posing a greater infection risk, especially if differ-
ent generations cohabit together. Lower income may also be as-
sociated with higher SARS- CoV- 2 transmission risks, for example, 
through reliance on public transport or through occupation.[60] 
Indeed, differences in the ability to reduce mobility and visiting 
more crowded points of interest may also account for higher in-
fection rates in disadvantaged racial and socioeconomic popula-
tions.[61] Researchers from Oxford, United Kingdom forecasted 
substantial and uneven wage losses all around Europe by COVID- 
19- related lockdown and social distancing periods.[62] They ex-
pressed concerns that poverty and wage inequality will rise in 
all European countries in the absence of compensating policies. 
Inequity in accessing healthcare services and healthy nutrition 
will be further consequences. Fully addressing these disparities is 
beyond the scope of this article.
3. Face masks combined with other preventive measures, such as 
frequent hand- washing and physical distancing, help to slow 
viral transmission.[63] In East Asia, mask- wearing to prevent 
the spread of infectious disease is commonplace. In Europe and 
North America, however, their use has been stigmatized for a long 
time. Face coverings have been associated with assuming a dif-
ferent identity, avoiding recognition, to exhibit modesty, having 
an infectious disease, and for cultural ceremonies.[64] Masks are 
costly and a limited supply of masks has been observed since the 
beginning of the pandemic. In November 2020, Spain, which has 
the second highest number of cumulative infections in Western 
Europe, reduced the value- added tax for masks to make them 
more affordable.[65] If mask costs need to be covered by indi-
viduals, differences in risk of contracting SARS- CoV- 2 are predict-
able based on socioeconomic status. A study from Italy reported 
that community knowledge about the use, reuse, disinfection 
and disposal of masks is in need of improvement.[66] Thus, it is 
mandatory to facilitate unlimited access to and educate the use of 
masks.
4. Lockdown periods are public health measures proven to reduce 
viral transmission through reduced human interaction.[67] Such 
drastic measures need to be accompanied by appropriate infor-
mation campaigns. Groups with lower health and technological 
literacy may require particular attention.
5. COVID- 19- related social stigma make this challenging situation 
even worse, resulting in more severe health problems and dif-
ficulties controlling a disease outbreak.[68] Stigma can result in 
hiding illness to avoid discrimination, prevent people from seek-
ing timely healthcare and discourage adoption of healthy behav-
iours. A large global study revealed that healthcare workers are 
significantly more likely to experience COVID- 19- related stigma 
and bullying, often in the context of racism, violence and police 
involvement in community settings.[69]
6. There is legitimate hope that a COVID- 19 vaccine will bring the 
pandemic under control, when combined with appropriate mass 
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testing and existing behavioural and non- behavioural prevention 
measures.[70] When it comes to distributing COVID- 19 vac-
cines,[71] the major challenge will be to prevent the inequality 
gaps the pandemic has exposed from widening. The decision as 
to whom to vaccinate first is a complex public health issue. In 
some settings, elderly people and people with comorbidities are 
being prioritized. In other settings, it may be populations most 
likely to become infected or more likely to be responsible for 
community spread who would be targeted.[72] Demand for 
COVID- 19 vaccines is likely to far exceed supply initially. More 
than 10 billion vaccines doses have been pre- ordered and distri-
bution has started. The 27 member states of the European Union 
together with five other countries account for about half of this 
order.[73] Notably, these countries account for only around 13% 
of the global population. COVAX, a global alliance seeking to en-
sure that low- and middle- income countries get adequate vac-
cine provision, has been able to secure vaccines for only around 
250 million people.[74] Considering anti- vaccine campaigns, 
clear communication on the basis for regulatory decisions in-
cluding clinical trial and surveillance data will be necessary to 
provide clarity on advantages and safeguards in place and avoid 
the spread of “fake news”. To some extent, scepticism towards 
vaccination may be cultural.[75] Appropriate explanation of po-
tential risks and uncertainties needs to be tailored to individual 
groups. Lessons have been learned from polio, tuberculosis and 
measles vaccination campaigns, for which it is notable that un-
equitable distribution was a major reason for lack of complete 
eradication.[76]
7. The discussion on a global strategy for equitable access to vac-
cination needs to be extended to the care of people infected with 
SARS- CoV- 2. The major challenge will be to ensure equality of 
access, especially in countries without universal health coverage. 
There is a risk that costs associated with diagnosis and treatment 
of COVID- 19 could further intensify disparities. For example, es-
tablished anti- inflammatory or antiviral therapy for SARS- CoV- 2 
infection confers costs and emerging treatments such as mono-
clonal antibodies or convalescent sera, if they were to prove ef-
fective in trials, higher costs still. This consideration needs to be 
extended to non- restricted access to hospital beds, intensive care 
unit and ventilators, and rehabilitation services.
8. Criticism has been voiced against the formulation and implemen-
tation of “ageist” policy, whereby resources are prioritized based 
exclusively on patients' chronological age.[77] Older people from 
lower- income backgrounds are more likely to suffer from chronic 
conditions, multimorbidity and frailty. Older people from mi-
nority or disadvantaged groups may therefore face double dis-
crimination, placing them in an extremely vulnerable situation. 
Self- isolating older adults are more likely to experience loneliness, 
difficulties obtaining food for a balanced diet, lack of exercise, and 
lower cognitive stimulation. These factors may considerably de-
crease their levels of resilience, leading to a cascade of physical 
and mental health problems, exacerbated by challenges maintain-
ing social care and community support.
CONCLUSIONS
The COVID- 19 pandemic has exposed various social determinants 
of health outcome and has hit already disadvantaged groups in a 
profound and disproportionate fashion. Lessons from previous epi-
demics and the current pandemic reinforce the need to implement 
mitigation measures. Some of the issues of direct relevance to neu-
rologists are outlined in this review. With this appraisal, the EAN 
NeuroCOVID- 19 Task Force intends to raise awareness of the po-
tential impact of COVID- 19 on inequalities in healthcare and calls for 
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